For the last decade, great advances have been made in our understanding of the cancerous process on a molecular basis. This progress was reflected in the high hopes that a ?final? solution (i.e. .the prevention or successful treatment of cancer) was imminent and relatively simple. But, trees don?t grow to the sky. The heterogeneity of malignant growth, for one, forces us to adopt more humility, patience and caution in our expectations. Evidently, cancer treatment requires far more than agents that selectively suppress cell proliferation or prevent mutagenesis. In fact, one answered question gives rise to more unanswered ones and ends up by undermining our confidence in existing models. The enthusiastic pursuit of newer and better agents is necessary, but is becoming increasingly costly: can and will we be able to afford it?
Go to Previous Page
Go to Next Page